{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:15:45Z","timestamp":1776867345475,"version":"3.51.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011421","name":"Sanofi China Investment Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40261-019-00750-3","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T06:06:52Z","timestamp":1548396412000},"page":"331-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China"],"prefix":"10.1007","volume":"39","author":[{"given":"Yan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Chirikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-3316","authenticated-orcid":false,"given":"Fen","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"750_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.msard.2013.09.004","volume":"3","author":"JD Campbell","year":"2014","unstructured":"Campbell JD, Ghushchyan V, Brett McQueen R, et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates. Mult Scler Relat Disord. 2014;3:227\u201336.","journal-title":"Mult Scler Relat Disord"},{"key":"750_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1756285610385608","volume":"3","author":"R Gold","year":"2010","unstructured":"Gold R, Wolinsky JS, Amato MP, Comi G. Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord. 2010;3:351\u201367.","journal-title":"Ther Adv Neurol Disord"},{"key":"750_CR3","doi-asserted-by":"publisher","first-page":"A387","DOI":"10.1016\/j.autrev.2009.11.010","volume":"9","author":"R Milo","year":"2010","unstructured":"Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9:A387\u201394.","journal-title":"Autoimmun Rev"},{"key":"750_CR4","unstructured":"National Multiple Sclerosis Society. Types of MS. 2012. at \n                    http:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS\n                    \n                  )."},{"key":"750_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.msard.2013.06.015","volume":"3","author":"N Makhani","year":"2014","unstructured":"Makhani N, Morrow S, Fisk J, et al. MS incidence and prevalence in Africa, Asia, Australia and New Zealand: a systematic review. Mult Scler Relat Disord. 2014;3:48\u201360.","journal-title":"Mult Scler Relat Disord"},{"key":"750_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000444019","volume":"46","author":"S Eskandarieh","year":"2016","unstructured":"Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple sclerosis epidemiology in east Asia, south east Asia and south Asia: a systematic review. Neuroepidemiology. 2016;46:209\u201321.","journal-title":"Neuroepidemiology"},{"key":"750_CR7","doi-asserted-by":"crossref","unstructured":"Cheong WL, Mohan D, Warren N, Reidpath DD. Multiple sclerosis in the Asia Pacific region: a systematic review of a neglected neurological disease. Frontiers in neurology 2018;9.","DOI":"10.3389\/fneur.2018.00432"},{"key":"750_CR8","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1212\/01.wnl.0000260695.72980.b7","volume":"68","author":"Q Cheng","year":"2007","unstructured":"Cheng Q, Miao L, Zhang J, et al. A population-based survey of multiple sclerosis in Shanghai, China. Neurology. 2007;68:1495\u2013500.","journal-title":"Neurology"},{"key":"750_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13023-016-0457-4","volume":"11","author":"X Liu","year":"2016","unstructured":"Liu X, Cui Y, Han J. Estimating epidemiological data of Multiple sclerosis using hospitalized data in Shandong Province, China. Orphanet J Rare Dis. 2016;11:73.","journal-title":"Orphanet J Rare Dis"},{"key":"750_CR10","unstructured":"Hu S, Donga P, Zhu G, Pan F, Wang C. The burden of multiple sclerosis in China: A literature review. Neurology Asia 2011;16."},{"key":"750_CR11","unstructured":"Neuroimmunology group of neurology branch for Chinese medical association and Neuroimmunology branch of China society of immunology. China expert consensus on Multiple sclerosis diagnosis and treatment (2014)[J]. Chin J Neurol, 2015, 48(5):362-367."},{"key":"750_CR12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/WNL.0000000000002441","volume":"86","author":"P O\u2019connor","year":"2016","unstructured":"O\u2019connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide Nine-year follow-up of the randomized TEMSO study. Neurology. 2016;86:920\u201330.","journal-title":"Neurology"},{"key":"750_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","volume":"5","author":"G Comi","year":"2016","unstructured":"Comi G, Freedman MS, Kappos L, et al. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016;5:97\u2013104.","journal-title":"Mult Scler Relat Disord"},{"key":"750_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40263-014-0207-x","volume":"29","author":"X Zhang","year":"2015","unstructured":"Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-beta1a in relapsing-remitting multiple sclerosis. CNS Drugs. 2015;29:71\u201381.","journal-title":"CNS Drugs"},{"issue":"537\u201357","key":"750_CR15","first-page":"e10","volume":"39","author":"E Soini","year":"2017","unstructured":"Soini E, Joutseno J, Sumelahti ML. Cost-utility of First-line disease-modifying treatments for relapsing-remitting multiple sclerosis. Clin Ther. 2017;39(537\u201357):e10.","journal-title":"Clin Ther"},{"key":"750_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/bmj.326.7388.522","volume":"326","author":"J Chilcott","year":"2003","unstructured":"Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis Commentary evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326:522.","journal-title":"BMJ"},{"key":"750_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u201352.","journal-title":"Neurology"},{"key":"750_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.15585\/mmwr.mm6702a4","volume":"67","author":"EB Rose","year":"2018","unstructured":"Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory syncytial virus seasonality\u2014United States, 2014\u20132017. Morb Mortal Wkly Rep. 2018;67:71.","journal-title":"Morb Mortal Wkly Rep"},{"key":"750_CR19","first-page":"502","volume":"12","author":"L Xia","year":"2015","unstructured":"Xia L, Li J-H, Zhao K, Wu H-Y. Incidence and in-hospital mortality of acute aortic dissection in China: analysis of China Health Insurance Research (CHIRA) data 2011. JGC. 2015;12:502.","journal-title":"JGC"},{"key":"750_CR20","doi-asserted-by":"publisher","first-page":"A728","DOI":"10.1016\/j.jval.2014.08.066","volume":"17","author":"Y Yang","year":"2014","unstructured":"Yang Y, Zhang J, Du F, Montgomery W, Li H, Flynn J. Real world evidence in mainland China: experience with the use of health care claims data. Value Health. 2014;17:A728.","journal-title":"Value Health"},{"key":"750_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293\u2013303.","journal-title":"N Engl J Med"},{"key":"750_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247\u201356.","journal-title":"Lancet Neurol"},{"key":"750_CR23","doi-asserted-by":"publisher","first-page":"e004073","DOI":"10.1136\/bmjopen-2013-004073","volume":"4","author":"J Palace","year":"2014","unstructured":"Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4:e004073.","journal-title":"BMJ Open"},{"key":"750_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1474-4422(15)00018-6","volume":"14","author":"J Palace","year":"2015","unstructured":"Palace J, Duddy M, Bregenzer T, et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6\u00a0years: a clinical cohort study with natural history comparator. Lancet Neurol. 2015;14:497\u2013505.","journal-title":"Lancet Neurol"},{"key":"750_CR25","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1212\/01.wnl.0000187122.71735.1f","volume":"65","author":"U Held","year":"2005","unstructured":"Held U, Heigenhauser L, Shang C, Kappos L, Polman C. Sylvia Lawry Centre for MSR Predictors of relapse rate in MS clinical trials. Neurology. 2005;65:1769\u201373.","journal-title":"Neurology"},{"key":"750_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jns.2017.08.403","volume":"381","author":"R Macdonell","year":"2017","unstructured":"Macdonell R, Freedman M, Xu X, et al. Efficacy and safety of teriflunomide in chinese patients with relapsing forms of ms: a subgroup analysis of the phase 3 tower study. J Neurol Sci. 2017;381:135.","journal-title":"J Neurol Sci"},{"key":"750_CR27","unstructured":"TA303: Teriflunomide for treating relapsing-remitting multiple sclerosis. 2014. at \n                    https:\/\/www.nice.org.uk\/Guidance\/ta303\n                    \n                  .)."},{"key":"750_CR28","unstructured":"TA312: Alemtuzumab for treating relapsing-remitting multiple sclerosis. 2014. at \n                    https:\/\/www.nice.org.uk\/guidance\/ta312?unlid=408428645201631253649\n                    \n                  .)."},{"key":"750_CR29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3111\/13696998.2015.1135805","volume":"19","author":"J Mauskopf","year":"2016","unstructured":"Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J Med Econ. 2016;19:432\u201342.","journal-title":"J Med Econ"},{"key":"750_CR30","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1524-4733.2008.00485.x","volume":"12","author":"P Tappenden","year":"2009","unstructured":"Tappenden P, McCabe C, Chilcott J, et al. Cost-Effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population. Value Health. 2009;12:657\u201365.","journal-title":"Value Health"},{"key":"750_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CEOR.S130334","volume":"9","author":"J Burks","year":"2017","unstructured":"Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. CEOR. 2017;9:251.","journal-title":"CEOR"},{"key":"750_CR32","doi-asserted-by":"publisher","first-page":"e0133279","DOI":"10.1371\/journal.pone.0133279","volume":"10","author":"K Hansen","year":"2015","unstructured":"Hansen K, Sch\u00fcssel K, Kieble M, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study. PLoS One. 2015;10:e0133279.","journal-title":"PLoS One"},{"key":"750_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458513507821","volume":"20","author":"P Vermersch","year":"2014","unstructured":"Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler J. 2014;20:705\u201316.","journal-title":"Mult Scler J"},{"key":"750_CR34","unstructured":"Park P, Hall N. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: Effectiveness and Value. 2017."},{"key":"750_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96\u2013120.","journal-title":"Mult Scler"},{"key":"750_CR36","unstructured":"Life tables by country\u2014China. World Health Organization. \n                    http:\/\/apps.who.int\/gho\/data\/?theme=main&vid=60340\n                    \n                  . Accessed 7 Apr 2018."},{"key":"750_CR37","first-page":"101","volume":"29","author":"RJ Pokorski","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insurance Med N Y. 1997;29:101\u20136.","journal-title":"J Insurance Med N Y"},{"key":"750_CR38","volume-title":"The clinical effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate in the management of relapsing\/remitting and secondary-progressive multiple sclerosis","author":"P Tappenden","year":"2006","unstructured":"Tappenden P, McCabe C, Simpson E, Chilcott J, Nixon R, Madan J. The clinical effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate in the management of relapsing\/remitting and secondary-progressive multiple sclerosis. Sheffield: The University of Sheffield; 2006."},{"key":"750_CR39","unstructured":"Notice of the Ministry of Human Resources and Social Security on the inclusion of 36 drugs in the Category B of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List. 2017. Website:\n                    http:\/\/www.mohrss.gov.cn\/yiliaobxs\/YILIAOBXSzhengcewenjian\/201707\/t20170718_274153.html\n                    \n                  . Accessed 29 Jul 2018."},{"key":"750_CR40","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40273-014-0150-1","volume":"32","author":"S Guo","year":"2014","unstructured":"Guo S, Pelligra C, Thibault CS, Hernandez L, Kansal A. Cost-effectiveness analyses in multiple sclerosis a review of modelling approaches. Pharmacol Econ. 2014;32:559\u201372.","journal-title":"Pharmacol Econ"},{"key":"750_CR41","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","volume":"26","author":"R Gani","year":"2008","unstructured":"Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26:617\u201327.","journal-title":"Pharmacoeconomics"},{"key":"750_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2165\/11592160-000000000-00000","volume":"5","author":"M Oleen-Burkey","year":"2012","unstructured":"Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Burden of a multiple sclerosis relapse. Patient-Patient-Centered Outcomes Res. 2012;5:57\u201369.","journal-title":"Patient-Patient-Centered Outcomes Res"},{"key":"750_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40258-014-0079-8","volume":"12","author":"TA Lavelle","year":"2014","unstructured":"Lavelle TA, Wittenberg E, Lamarand K, Prosser LA. Variation in the spillover effects of illness on parents, spouses, and children of the chronically ill. Appl Health Econ Health Policy. 2014;12:117\u201324.","journal-title":"Appl Health Econ Health Policy"},{"key":"750_CR44","first-page":"1","volume":"5","author":"L Hernandez","year":"2018","unstructured":"Hernandez L, O\u2019Donnell M, Postma M. Modeling approaches in cost-effectiveness analysis of disease-modifying therapies for relapsing\u2013remitting multiple sclerosis: an updated systematic review and recommendations for future economic evaluations. Pharmacol Econ. 2018;5:1\u201330.","journal-title":"Pharmacol Econ"},{"key":"750_CR45","doi-asserted-by":"publisher","first-page":"A434","DOI":"10.1016\/j.jval.2016.09.506","volume":"19","author":"J Ord\u00f3\u00f1ez","year":"2016","unstructured":"Ord\u00f3\u00f1ez J, Serafini P, Machado M. Cost-utility analysis of dimethyl fumarate versus fingolimod and teriflunomide in patients with relapsing-remitting multiple sclerosis in Colombia. Value Health. 2016;19:A434.","journal-title":"Value Health"},{"key":"750_CR46","doi-asserted-by":"publisher","first-page":"A723","DOI":"10.1016\/j.jval.2017.08.1946","volume":"20","author":"S Taheri","year":"2017","unstructured":"Taheri S, Yousefi N, Sahraian M, Mehralian G. Cost-effectiveness analysis of alemtuzumab in comparison with natalizumab, intramuscular interferon beta-1a, subcutaneous interferon beta-1b, and fingolimod for the treatment of relapsing-remitting multiple sclerosis in Iran. Value in Health. 2017;20:A723.","journal-title":"Value in Health"},{"key":"750_CR47","doi-asserted-by":"publisher","first-page":"A724","DOI":"10.1016\/j.jval.2017.08.1951","volume":"20","author":"J Lee","year":"2017","unstructured":"Lee J, Ko S. The cost effectiveness of fingolimod for the treatment multiple sclerosis in Korea. Value Health. 2017;20:A724.","journal-title":"Value Health"},{"key":"750_CR48","unstructured":"Alskaabi MF. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia: University of Toledo; 2017."},{"key":"750_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/1352458517708668","volume":"23","author":"A Boyko","year":"2017","unstructured":"Boyko A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Russia. Mult Scler J. 2017;23:155\u201365.","journal-title":"Mult Scler J"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00750-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00750-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00750-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T19:18:08Z","timestamp":1579893488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00750-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["750"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00750-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"25 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Sanofi China. However, publication of the study results was not contingent on sponsor\u2019s approval. All authors contributed to the development of the publication and maintained control over the final content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Viktor Chirikov, Fen Du, Yu-Chen Yeh, and Xin Gao are employees of Pharmerit International, which received funding from Sanofi China to conduct this research. Li Liu and Ruiqi Liu are employees of Sanofi China. Yan Xu and Ningying Mao report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}